

## Supporting Information

### General Remarks

PSCaa **1** was synthesized as described previously.<sup>[1]</sup> The synthesis of Keto-PSCaa **2** and Cl-PSCaa **3** will be described elsewhere. Primers were obtained from IDT or Valuegene.

### Library construction

Overlapping PCRs were performed on the *M. mazei* PylRS gene to randomize the codons for each selected active site residue using oligonucleotides containing NNK, SYT or GBT at each site destined for mutagenic diversification. The amplified full-length PCR product was ligated into the pre-cut pBK5-MmPylRS<sup>[2]</sup> plasmid to afford the mutant DNA library CRIZ. The library was electroporated into DH10 $\beta$ T1 competent cells harboring pREP selection plasmid. Selection was carried out on GMMML plates containing 12.5  $\mu\text{g mL}^{-1}$  tetracycline, 50  $\mu\text{g mL}^{-1}$  kanamycin, 40  $\mu\text{g mL}^{-1}$  chloramphenicol and 1 mM PSCaa as previously described.<sup>[2]</sup>

Primers used in library construction are the following with mutated residues highlighted in yellow:

302R: 5' -GGGCACGGTCCAGTTTACGMNNATAGTTGTACAGGTTCCGGAGDCAGCAT-3'

309R: 5' -GGGCACGGTCCAGTTTACGMNNATAGTTGTACAGGTTCCGGAGTCAGCATCCG-3'

322F: 5' -GTAAACTGGACCGTGCCCTGCCGGACCCGATCAAA~~NNK~~TTCGAGATCGGTCCTTGC-3'

346R: 5' -CAGCATGGTGAATTCTTCCAG-3'

346/348F: 5' -CTGGAAGAATTCACCATGCTG~~SYT~~TTC~~GBT~~CAGATGGGTAGCGGTTGC-3'

401R: 5' -TGCGGAAGACAGCTCCAG-3'

401F: 5' -CTGGAGCTGTCTTCCGCA~~SYT~~GTGGGCCCAATCCCGCTGGATCGTGAGTGGGGTATCGAC-3'

417/419F: 5' -GATCGTGAGTGGGGTATCGACAAACCT~~NNK~~ATC~~GBT~~GCGGGTTTTGGTCTGGAGCGTCTG-3'

### Protein Expression and Uaa Incorporation in *E. coli*

To translationally incorporate Uaas into myoglobin in *E. coli*, BL21 cells were transformed with plasmids pTak-Myo4TAG and pBK-MmPSCaaRS (or pBK-MmKetoPSCaaRS). For each sample, a colony was picked and grown overnight in 5 mL 2xYT supplemented with 30  $\mu\text{g mL}^{-1}$  chloramphenicol and 50  $\mu\text{g mL}^{-1}$  kanamycin at 37 °C. This starter culture was used to inoculate 50 mL of 2xYT containing antibiotics. When OD<sub>600</sub> reached 0.5, 1 mM of the corresponding unnatural amino acid was added, and cells were induced for protein expression by adding 0.5  $\mu\text{M}$  IPTG. After 5 h, cells were lysed and sonicated in 5 mL lysis buffer (50 mM TrisHCl, pH 8.0, 500 mM NaCl, 20 mM imidazole pH 8.0, 1% (v/v) Tween 20, 10% (v/v) glycerol and 0.5 mg mL<sup>-1</sup> lysozyme). Lysed cells were centrifuged for 20 min at 14,000 g, and clarified supernatant was passed through a 0.1 mL column of Ni<sup>2+</sup>-NTA agarose resin (Qiagen). The column was washed with 10 column volumes of wash buffer (lysis buffer without Tween

20 and lysozyme). Protein was eluted with 400  $\mu$ L of elution buffer (wash buffer containing 250 mM imidazole, pH 8.0). The sample was concentrated using a Microcon Ultracel YM-10 spin column (Millipore). To incorporate PSCaas into GFP, DH10 $\beta$  cells were transformed with pTak-GFPtag and pBK-MmPSCaaRS. To incorporate Cl-PSCaa **3** into CaM, plasmids pTak-CaM-76TAG and pBK-MmPSCaaRS were transformed into BL-21 cells, and proteins were purified with Ni<sup>2+</sup>-NTA agarose resin using similar procedures.

### Mass spectrometry

The protein samples of myoglobin were desalted on a ZIP tip (Millipore) and analysed by high-resolution Fourier-transform MS on a Thermo LTQ-Orbitrap XL mass spectrometer (ThermoFisher, San Jose, CA). The sample was loaded onto a capillary column (75 mm diameter) with an integrated spray tip, which was filled with reversed phase material (Zorbax SB C-18, particle size 5 mm, bed length 5 cm). Protein was eluted with a gradient of 0.1% formic acid and an increasing proportion of acetonitrile at a flow rate of 300 nL min<sup>-1</sup>. The eluate was electrosprayed directly into the mass spectrometer. Fourier-transform mass spectra were recorded at a resolution of 60000 for a scan range of m/z 400–1800 followed by a select ion scan of the most intense ion at resolution 60000. Data were charge-deconvoluted using the Thermo Qualbrowser 2.0 Xtract program. Intact proteins of CaM were analyzed by ESI-TOF using an Agilent 6210 mass spectrometer coupled to an Agilent 1100 HPLC system. Two micrograms of protein samples were injected by an auto-sampler and separated on an Agilent Zorbax SB-C8 column (2.1 mm ID  $\times$  10 cm length) by a reverse-phase gradient of 0–80% acetonitrile for 15 min. Mass calibration was performed right before the analysis. Protein spectra were averaged and the charge states were deconvoluted using Agilent MassHunter software.

### Uaa incorporation in mammalian cells

Genes for MmPylRS and MmPSCaaRS were subcloned into plasmid pMPcua-OmeRS between the *Xho* I and *Nhe* I sites using primers MmPylRS *Xho*I and MmPylRS *Nhe*I.<sup>[2]</sup> The HeLa-GFP(182TAG) stable cells were transfected with the resultant pMPcua-MmPylRS and pMPcua-MmPSCaaRS. Cells were grown in DMEM supplemented with 10% FBS; 0.1 mM of PSCaa was added to or withheld from the media. Cells were imaged 48 h after transfection with an Olympus IX8I microscope equipped with a Hamamatsu EM-CCD under the same image capture conditions for all samples ( $\lambda_{\text{ex}} = 480 \pm 20$  nm,  $\lambda_{\text{em}} = 535 \pm 40$  nm). Transfected HeLa cells were trypsinized and washed with PBS twice. After suspending in 1.0 mL PBS and 5  $\mu$ L of propidium iodide, cells were analysed with a FACScan (Becton & Dickinson, excitation 488 nm, emission 530  $\pm$  30 nm). For each sample the total fluorescence intensity of 10,000 cells was recorded and normalized to cells transfected with pMPcua-MmPylRS with Boc-Lys added.


## **Molecular docking**

For MmPSCaaRS and MmKetoPSCaaRS, protein models bearing the selected amino-acid substitutions were generated from the 3QTC template. Initially, the replacement side-chains were introduced with a suitable preferred conformation in the program Coot<sup>[3]</sup> and the target Uaa ligand was positioned roughly as guided by the Ome in 3QTC, and these atomic groups were then manually adjusted to minimize steric conflicts. The initial synthetase-Uaa complexes were subsequently subjected to one round of simple dynamics with pdbtools in the program Phenix.<sup>[4]</sup>


## **Photoisomerization**

UV/visible and circular dichroism (CD) spectra of the photoswitchable CaM were measured at a protein concentration of 7  $\mu$ M on a Bio-Logic MOS450 spectrometer in Na-phosphate (10 mM) buffer containing NaF (100 mM) and at pH 7.5 using a 0.1 cm quartz cuvette (Helma) at 25 °C. The UV and CD spectrum of the pure *trans*-isomer was recorded upon storage in the dark at room temperature. The UV/visible and CD spectrum of the photostationary state of the *cis* state was recorded after illumination at 365 nm for 2 min at 25 °C.

A)



B)




**Figure S1.** a) Fluorescence imaging of clones streaked on LB plates without PSCaa (left plate) and with 1 mM PSCaa (right plate). b) Western blot analysis of GFP expression by identified clones. Cell lysates were separated by SDS-PAGE and probed with an anti-His antibody (Samples were normalized for constant cell numbers for each lane). Clone 5 lacks exclusive specificity for the PSCaa, as determined by fluorescence and Western blot. Other clones showed PSCaa-dependent GFP fluorescence and expression. Clone D was used for further studies and named MmPSCaaRS.


Position	#A		#B		#D		#E		#G		#H	
	codon	AA	codon	AA	codon	AA	codon	AA	codon	AA	codon	AA
302	TCT	S	ACT	T	ACT	T	ACT	T	ACT	T	TCT	S
309	GCG	A	GCT	A	TCG	S	TCG	S	TCT	S	GGG	G
322	GTT	V	ACT	T	ATT	I	CTT	L	TTG	L	CTG	L
346	GCT	A	GCT	A	GTT	V	GTT	V	GTT	V	GCT	A
348	GGT	G	GGT	G	GGT	G	GGT	G	GGT	G	GGT	G
401	GTT	V	GTT	V	GTT	V	GTT	V	GTT	V	GGT	V
417	TGG	W	TGG	W	TGG	W	TGG	W	TGG	W	TGG	W
419	GGT	G	GGT	G	GGT	G	GGT	G	GGT	G	GGT	G

Position	#I		#J		#K		#L		#1		#7	
	codon	AA	codon	AA	codon	AA	codon	AA	codon	AA	codon	AA
302	TCT	S	ACT	T	ACT	T	TCT	S	ACT	T	TCT	S
309	GCG	A	AGT	S	TCT	S	TCG	S	GCT	A	GCG	A
322	GTT	V	ATT	I	TTG	L	CTG	L	TTG	L	GTT	V
346	GCT	A	GTT	V	GTT	V	GCT	A	GCT	A	GCT	A
348	GGT	G	GGT	G	GGT	G	GGT	G	GGT	G	GGT	G
401	GTT	V	GTT	V	GTT	V	GTT	V	GTT	V	GGT	V
417	TGG	W	TGG	W	TGG	W	TGG	W	TCG	S	TGG	W
419	GGT	G	GGT	G	GGT	G	GCT	A	GGT	G	GGT	G


**Table S1.** Sequencing of clones obtained after selection for PSCaa. Converged clones are boxed with the same color. Identical substitutions at four sites in multiple hits are highlighted in yellow. Clone #D was used for incorporation of PSCaa (MmPSCaaRS). Clone #B was used to incorporate the Keto-PSCaa 2 (MmKetoPSCaaRS).




**Figure S2.** Western blot screen for clones incorporating Uaa 2. GFP expression in the presence or absence of 2 (1 mM) was detected by probing the cell lysates separated by SDS-PAGE with an anti-His antibody (Samples were normalized for constant cell numbers for each lane). Clone B was named MmKetoPSCaaRS for further studies.



**Figure S3.** Specific incorporation of Keto-PSCaa **2** into myoglobin by the tRNA<sup>Pro</sup><sub>CUA</sub>-MmKetoPSCaaRS pair. A) SDS-PAGE analysis of myoglobin expression in the presence or absence of 1 mM Keto-PSCaa **2** in the growth medium. Samples were normalized for constant cell numbers for each lane. Arrow indicates the full-length myoglobin protein. B) High resolution ESI-FT MS analysis of the expressed myoglobin. Average and monoisotopic (indicated by MI) masses are labelled. A peak with a monoisotopic mass of 18624.84 Da was observed, which corresponds to intact myoglobin having a single Keto-PSCaa residue at position 4 (expected  $[M+H]^+ = 18624.81$  Da). The second peak observed corresponds to the Keto-PSCaa-containing myoglobin lacking the beginning Met (expected  $[M-Met+H]^+ = 18493.81$  Da, measured 18493.78 Da). Deamidation and decarboxylation peaks for the  $[M-Met+H]^+$  species were also detected and labelled. Notably, no peaks corresponding to myoglobin proteins containing any other amino acids at the amber codon position were observed.




**Figure S4.** Molecular docking of Keto-PSCaa **2** into a MmKetoPSCaaRS model built from 3QTC bearing the identified substitutions. Recognition of the main chain and the azobenzene moiety of **2** is similar to that of PSCaa **1**, as described in Figure 4 and in the text. Notably, T322 in MmKetoPSCaaRS may hydrogen bond with the keto oxygen of Keto-PSCaa **2**. In mutant synthetases specific for PSCaa **1** and Keto-PSCaa **2**, residue 309 and 322 are substituted by various distinct amino acids (Ala, Gly, or Ser309; and Ile, Leu, Thr, or Val322), whereas in PylRS mutants specific for Phe analogues bearing shorter side chains (Ome, Bpa, and Nap),<sup>[2][5]</sup> these two residues aptly are not substituted and retain the residue identities (Leu309 and Ile322) of wild-type PylRS. This difference is consistent with the location of these two residues deeper in the binding pocket and in contact with the second phenyl ring and the meta-substituent of PSCaas.



**Figure S5.** LC-MS monitoring of the crosslinking reaction between Cl-PSCaa **3** and Boc-protected cysteine **4**. A) Scheme showing the crosslinking reaction carried out in 1 M NaHCO<sub>3</sub> at pH 7.5. B) UV chromatogram at different time points of the reaction. C) m/z measured for the peak containing product **5**.





**Figure S6.** Influence of bridge photoisomerization on the protein conformation of CaM analyzed by CD spectroscopy. When the bridge was photoisomerized from the *trans* form (black line) to the *cis* form (red line), the negative ellipticity for CaM decreased, indicating a decrease in helix content of CaM.

#### Supporting References:

- [1] C. Hoppmann, P. Schmieder, N. Heinrich, M. Beyermann, *ChemBioChem* **2011**, *12*, 2555–2559.
- [2] J. K. Takimoto, N. Dellas, J. P. Noel, L. Wang, *ACS Chem. Biol.* **2011**, *6*, 733-743.
- [3] P. Emsley, K. Cowtan, *Acta Crystallogr. D. Biol. Crystallogr.* **2004**, *60*, 2126-2132.
- [4] P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, *Acta Crystallogr. D. Biol. Crystallogr.* **2010**, *66*, 213-221.
- [5] V. K. Lacey, G. V. Louie, J. P. Noel, L. Wang, *ChemBioChem* **2013**, *14*, 2100-2105.